tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Nail Diseases D009260 2 associated lipids
Paronychia D010304 3 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dyspnea D004417 10 associated lipids
Vascular Diseases D014652 16 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Listeriosis D008088 12 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Ascites D001201 25 associated lipids
Albuminuria D000419 18 associated lipids
Anemia D000740 21 associated lipids
Osteomalacia D010018 5 associated lipids
Tremor D014202 15 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Vasculitis D014657 14 associated lipids
Hypothermia D007035 19 associated lipids
Parkinson Disease D010300 53 associated lipids
Down Syndrome D004314 18 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Keloid D007627 12 associated lipids
Nephritis D009393 19 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Respiration Disorders D012120 5 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Facial Neoplasms D005153 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Influenza, Human D007251 11 associated lipids
Immune System Diseases D007154 3 associated lipids
Headache D006261 4 associated lipids
Cystitis D003556 23 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
HIV Infections D015658 20 associated lipids
Drug Eruptions D003875 30 associated lipids
Folliculitis D005499 7 associated lipids
Blindness D001766 6 associated lipids
Oliguria D009846 2 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Graves Disease D006111 6 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Gout D006073 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Choline Deficiency D002796 16 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Biliary Fistula D001658 13 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Renal Insufficiency D051437 8 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Moon BJ et al. Effect of chronic rhinosinusitis on liver transplant patients. 2009 Sep-Oct Am J Rhinol Allergy pmid:19807981
Shin JH et al. The effect of topical FK506 (tacrolimus) in a mouse model of allergic rhinitis. 2012 Mar-Apr Am J Rhinol Allergy pmid:22487280
Vearrier D et al. Mutism and persistent dysarthria due to tacrolimus-based immunosuppression following allogeneic liver transplantation. 2011 Am J Ther pmid:20535006
Yang A and Wang B Sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids: focus on acute rejection, patient and graft survival. Am J Ther pmid:23921809
Pariser D Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. 2009 May-Jun Am J Ther pmid:19262357
Sathyan S et al. Prevention of recurrent episodes of rhabdomyolysis with tacrolimus in a transplant recipient with myopathy. Am J Ther pmid:23429166
Liu JY et al. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Am J Ther pmid:25299636
Haroon N et al. Tacrolimus Toxicity With Minimal Clinical Manifestations: A Case Report and Literature Review. Am J Ther pmid:25730156
Nunokawa T et al. Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report. Am J Ther pmid:22836123
Liu JY et al. Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Am J Ther pmid:25569597
Cohen SM Current immunosuppression in liver transplantation. 2002 Mar-Apr Am J Ther pmid:11897926
Yousuf Bhat Z et al. Colchicine-Induced Myopathy in a Tacrolimus-Treated Renal Transplant Recipient: Case Report and Literature Review. Am J Ther pmid:24732905
Azizian M et al. Augmentation of ischemia/reperfusion injury to endothelial cells by cyclosporin A. 2004 Am Surg pmid:15156953
Henderson CN et al. Continuous Abdominal Irrigation for Treatment of Tertiary Peritonitis in the Immunosuppressed Patient after Solid Organ Transplant: A Novel Approach. 2017 Am Surg pmid:28424115
Rojas-García P et al. Breast fibroadenomas associated with immunosuppressive drugs. 2010 Am Surg pmid:21418766
Kodama M et al. FK506 therapy of experimental autoimmune myocarditis after onset of the disease. 1993 Am. Heart J. pmid:7504393
Chieffo A et al. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents. 2009 Am. J. Cardiol. pmid:19962471
Chang RK et al. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. 1998 Am. J. Cardiol. pmid:9604971
Klauss V et al. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. 2000 Am. J. Cardiol. pmid:10955391
Herzberg GZ et al. Usefulness of tacrolimus versus cyclosporine after pediatric heart transplantation. 1998 Am. J. Cardiol. pmid:9723652
Hisamura F et al. Synergistic effect of green tea polyphenols on their protection against FK506-induced cytotoxicity in renal cells. 2008 Am. J. Chin. Med. pmid:18543393
Chung SY et al. Ginkgo biloba leaf extract (EGb761) combined with neuroprotective agents reduces the infarct volumes of gerbil ischemic brain. 2006 Am. J. Chin. Med. pmid:17080546
Stickle DF et al. Effects of sterilizing gamma irradiation on bloodspot newborn screening tests and whole blood cyclosporine and tacrolimus measurements. 2003 Am. J. Clin. Pathol. pmid:12580001
Wang E et al. Pseudo-Pelger-Huët anomaly induced by medications: a clinicopathologic study in comparison with myelodysplastic syndrome-related pseudo-Pelger-Huët anomaly. 2011 Am. J. Clin. Pathol. pmid:21228370
Burke MT et al. Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients. 2015 Am. J. Clin. Pathol. pmid:25780003
Lower DR et al. Comparison of CEDIA FK506 assay with HPLC/MS/MS in a large cohort of pediatric patients. 2013 Am. J. Clin. Pathol. pmid:23690122
Rudi J et al. Prevalence of serum antibodies to Helicobacter pylori and to CagA protein in liver transplant recipients. 1997 Am. J. Gastroenterol. pmid:9317070
Van Thiel DH et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7532912
Baumgart DC et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. 2006 Am. J. Gastroenterol. pmid:16573777
Sandborn WJ Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. 1997 Am. J. Gastroenterol. pmid:9149205
Van Thiel DH et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7537444
Fellermann K et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). 1998 Am. J. Gastroenterol. pmid:9772045
Nara M et al. Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3. 2010 Am. J. Hematol. pmid:20568249
Lekakis LJ et al. BK virus nephropathy after allogeneic stem cell transplantation: a case report and literature review. 2009 Am. J. Hematol. pmid:19208419
Hammerstrom AE et al. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. 2013 Am. J. Hematol. pmid:23460378
Abdel-Azim H et al. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. 2015 Am. J. Hematol. pmid:26242764
Uehara T et al. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection. 2004 Am. J. Hematol. pmid:15282671
Nakamae H et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. 2006 Am. J. Hematol. pmid:16755559
Bolaños-Meade J et al. Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of the lung. 2005 Am. J. Hematol. pmid:15929116
Ninan MJ and Datta YH Post-transplant lymphoproliferative disorder presenting as multiple myeloma. 2010 Am. J. Hematol. pmid:20578201
Mach-Pascual S et al. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. 1996 Am. J. Hematol. pmid:8701950
Uehara T et al. A successful second unrelated BMT (UBMT) from a different unrelated donor to treat ALL that relapsed after the initial UBMT. 2002 Am. J. Hematol. pmid:12221672
Cohen DL et al. Pulse wave analysis to assess vascular compliance changes in stable renal transplant recipients. 2004 Am. J. Hypertens. pmid:15001192
Zhang W and Victor RG Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. 2000 Am. J. Hypertens. pmid:10981550
Taler SJ et al. Loss of nocturnal blood pressure fall after liver transplantation during immunosuppressive therapy. 1995 Am. J. Hypertens. pmid:7544983
Birdwell KA et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. 2009 Am. J. Kidney Dis. pmid:19185404
Rostaing L et al. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. 2016 Am. J. Kidney Dis. pmid:26717860
van Duijnhoven EM et al. A late episode of post-transplant diabetes mellitus during active hepatitis C infection in a renal allograft recipient using tacrolimus. 2002 Am. J. Kidney Dis. pmid:12087579
Neylan JF et al. Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine. 1998 Am. J. Kidney Dis. pmid:9820446
Paoletti E et al. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. 2007 Am. J. Kidney Dis. pmid:17591533